# On Open-Label Study in Participants With Systemic Lupus Erythematosus

> **NCT01488708** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 1518 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Connective Tissue Disease
- Autoimmune Disease

## Interventions

- **DRUG:** LY2127399
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01488708
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 1518 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01488708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01488708, "On Open-Label Study in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01488708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*